Category:Other Chemotherapy and Cancer Drugs

	Drug Name	Clinical Trial Phase	Common Side Effects	OS with	OS without	Usefulness Rating
BCNU (Carmustine) and Gliadel (Carmustine Wafers)	BCNU (Carmustine) and Gliadel (Carmustine Wafers)	Phase III (Europe for Gliadel)	Low blood counts, pulmonary problems, infection, and seizures for Gliadel	Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months	Not specified	4
Bevacizumab (Avastin)	Bevacizumab (Avastin)	Phase III	Hypertension, proteinuria, and hemorrhage	AVAglio trial: 16.8 months; RTOG trial: 15.7 months	Not specified	4
CCNU (Lomustine)	CCNU (Lomustine)	Phase 3 (Germany)	Hematological toxicity, nausea, vomiting, and pulmonary toxicity	23 months median survival, with 47% at 2 years	Not specified	4
Gleevec (Imatinib)	Gleevec (Imatinib)	Exploratory/Investigational (Specific phase for gliomas not provided)	Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population.	Not applicable; studies focusing on PFS-6 as a primary endpoint	Not specified	3
Platinum Compounds	Platinum Compounds	Various, including Phase II	Nephrotoxicity, ototoxicity, and neurotoxicity	Not specified	Not specified	3
Procarbazine	Procarbazine	Not specified	Hematological toxicity, nausea, and neurological effects	Not specified	Not specified	3

Pages in category "Other Chemotherapy and Cancer Drugs"

The following 6 pages are in this category, out of 6 total.